Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CLYM is expected to report earnings to rise 10.78% to -19 cents per share on November 11
Q3'26
Est.
$-0.20
Q2'26
Beat
by $0.03
Q1'26
Beat
by $0.09
Q4'25
Missed
by $0.07
Q3'25
Missed
by $0.04
The last earnings report on August 06 showed earnings per share of -18 cents, beating the estimate of -20 cents. With 711.25K shares outstanding, the current market capitalization sits at 674.30M.